Saturday, 31 October 2026European Markets

CLOUDBERRY CLEAN Stock Jumps By 32% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of CLOUDBERRY CLEAN (Oslo Børs Benchmark Index_GI: CLOUD.OL) jumped by a staggering 32% in 21 sessions from kr10.5 to kr13.86 at 14:25 EST on Monday, after three successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is dropping 0.32% to kr1,227.59, after three sequential sessions in a row of gains.

About CLOUDBERRY CLEAN

Cloudberry Clean Energy ASA operates as a renewable energy company. It operates through four segments: Production, Development, Operations and Corporate. The company engages in the ownership, development, and operation of hydropower plants and wind farms in Norway, Sweden, and Denmark. Cloudberry Clean Energy ASA was incorporated in 2017 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, CLOUDBERRY CLEAN has a trailing twelve months EPS of kr0.92.

PE Ratio

CLOUDBERRY CLEAN has a trailing twelve months price to earnings ratio of 15.07. Meaning, the purchaser of the share is investing kr15.07 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for CLOUDBERRY CLEAN is 361817 which is 63.24% below its average volume of 274373.

More news about CLOUDBERRY CLEAN (CLOUD.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com